RxDoctor Payments DataLook up a doctor →

Pedram Hamrah, MD

Ophthalmology · Tampa, FLNPI 1366483778

Payments from drug & device makers

$2,243,520in general payments, 2019–2025

Across 261 payments — averaging $8595.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$1M
  • Dompe Farmaceutici S.p.a.$780K
  • Novartis$207K
  • Ocular Therapeutix, Inc.$112K
  • Bausch Health US, LLC$23K
  • E.r. Squibb & Sons, L.L.C.$19K
  • plus $87K from 19 others

What the payments were for

  • Consulting fees$168,84990%
  • Speaking & faculty fees$9,1945%
  • Travel & lodging$4,4282%
  • Food & beverage$4,3232%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,243,520 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$112,381
Medicare patients
372
Services billed
987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj76$2,438,779
MieboPerfluorohexyloctane/Pf178$218,975
RestasisCyclosporine186$210,917
Loteprednol Etabonate393$73,734
Cyclosporine94$44,953
XiidraLifitegrast42$28,502
LotemaxLoteprednol Etabonate58$19,557
TyrvayaVarenicline Tartrate24$17,626
VevyeCyclosporine17$17,450
CequaCyclosporine15$9,882
AzasiteAzithromycin16$9,545
Lotemax SmLoteprednol Etabonate35$9,280
RhopressaNetarsudil Mesylate19$9,039
AlrexLoteprednol Etabonate14$4,789
Prednisolone Acetate90$4,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$1,014,845$2,438,77976 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$397$247,477220 claims
AbbVieRestasis$4,360$210,917186 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Lotemax Sm, Alrex$135$107,359500 claims
Oyster Point Pharma, Inc.Tyrvaya$140$17,62624 claims
Sun Pharmaceutical Industries Inc.Cequa$77$9,88215 claims
Aerie Pharmaceuticals, Inc.Rhopressa$1,600$9,03919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →